Literature DB >> 3109316

Altered metabolic properties of cultured skin fibroblasts in Alzheimer's disease.

N R Sims, J M Finegan, J P Blass.   

Abstract

Alzheimer's disease is associated with selective neuronal loss, the cause of which is undetermined. Evidence indicating a predisposing genetic factor associated with this disease suggests that important alterations may be expressed in tissues other than the brain. Because abnormal glucose and energy-related metabolism have been identified in both in vivo and in vitro studies of brain, we conducted a study to examine related measures in cultured skin fibroblasts from six patients with Alzheimer's disease and seven age-matched controls. After 60 minutes' incubation, the production of 14CO2 from [U-14C]glucose and lactate production were significantly higher in the cells from the group of patients with Alzheimer's disease. The increase of 14CO2 production, but not the production of lactate, was most evident after a more rapid period of metabolic activity in the first 10 minutes of incubation. By contrast, 14CO2 production from [U-14C]glutamine, which is probably the major substrate of oxidative metabolism in these cells, was significantly reduced in the Alzheimer's disease cells following longer (120-minute) incubations. Oxygen uptake by cell suspensions was also significantly reduced in the group with Alzheimer's disease. These results indicate that complex metabolic differences are expressed in nonneural tissues from some patients with Alzheimer's disease and may provide important clues to the pathogenesis of this disorder.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3109316     DOI: 10.1002/ana.410210507

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  18 in total

Review 1.  Genetic risk factors in Alzheimer's disease.

Authors:  L Tilley; K Morgan; N Kalsheker
Journal:  Mol Pathol       Date:  1998-12

Review 2.  The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives.

Authors:  Russell H Swerdlow; Jeffrey M Burns; Shaharyar M Khan
Journal:  Biochim Biophys Acta       Date:  2013-09-23

Review 3.  Systemic and brain metabolic dysfunction as a new paradigm for approaching Alzheimer's dementia.

Authors:  Vincenzo Giordano; Gianfranco Peluso; Maurizio Iannuccelli; Paola Benatti; Raffaella Nicolai; Menotti Calvani
Journal:  Neurochem Res       Date:  2006-08-17       Impact factor: 3.996

Review 4.  Mitochondria-associated ER membranes and Alzheimer disease.

Authors:  Estela Area-Gomez; Eric A Schon
Journal:  Curr Opin Genet Dev       Date:  2016-05-25       Impact factor: 5.578

5.  Alterations in mitochondrial number and function in Alzheimer's disease fibroblasts.

Authors:  Nora E Gray; Joseph F Quinn
Journal:  Metab Brain Dis       Date:  2015-04-12       Impact factor: 3.584

Review 6.  Mitochondria and cell bioenergetics: increasingly recognized components and a possible etiologic cause of Alzheimer's disease.

Authors:  Russell H Swerdlow
Journal:  Antioxid Redox Signal       Date:  2011-09-15       Impact factor: 8.401

7.  Significantly reduced expression of the proteoglycan decorin in Alzheimer's disease fibroblasts.

Authors:  E Brandan; F Melo; M García; M Contreras
Journal:  Clin Mol Pathol       Date:  1996-12

Review 8.  Mitochondria, Cybrids, Aging, and Alzheimer's Disease.

Authors:  R H Swerdlow; S Koppel; I Weidling; C Hayley; Y Ji; H M Wilkins
Journal:  Prog Mol Biol Transl Sci       Date:  2017-02-01       Impact factor: 3.622

9.  Internal Ca2+ mobilization is altered in fibroblasts from patients with Alzheimer disease.

Authors:  E Ito; K Oka; R Etcheberrigaray; T J Nelson; D L McPhie; B Tofel-Grehl; G E Gibson; D L Alkon
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-18       Impact factor: 11.205

10.  Late-onset Alzheimer's disease is associated with inherent changes in bioenergetics profiles.

Authors:  Kai-C Sonntag; Woo-In Ryu; Kristopher M Amirault; Ryan A Healy; Arthur J Siegel; Donna L McPhie; Brent Forester; Bruce M Cohen
Journal:  Sci Rep       Date:  2017-10-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.